Total Funding
40
77
Total FundingSeed raised
Growth Score
-7 pts
Heat Score
-14 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
134800
Black Swan Pharmaceuticals is dedicated to discovering and progressing innovative gene targeting therapeutics for neurological disorders.
Craig Metz: Co-Founder, Chief Executive Officer & Board Member
About the Company
Black Swan Pharmaceuticals is dedicated to discovering and progressing innovative gene-targeting therapeutics for neurological disorders. It was incorporated in 2018, is the realization of an initiative, led by Prof Anthony Akkari in partnership with the Perron Institute to accelerate the ground-breaking research occurring at its Motor Neurone
Research Laboratory and other research institutes in Western Australia. The BSP business model will efficiently and economically progress these assets from the discovery setting to US FDA Investigational New Drug Application (IND) submission readiness divestiture for initiation of clinical development.
